VolitionRx Statistics
Total Valuation
VolitionRx has a market cap or net worth of $4.07 million. The enterprise value is $12.69 million.
| Market Cap | 4.07M |
| Enterprise Value | 12.69M |
Important Dates
The last earnings date was Thursday, August 13, 2026, after market close.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
VolitionRx has 8.33 million shares outstanding. The number of shares has increased by 44.16% in one year.
| Current Share Class | 8.33M |
| Shares Outstanding | 8.33M |
| Shares Change (YoY) | +44.16% |
| Shares Change (QoQ) | +33.01% |
| Owned by Insiders (%) | 5.07% |
| Owned by Institutions (%) | 27.28% |
| Float | 6.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.65 |
| Forward PS | 1.56 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.30
| Current Ratio | 0.30 |
| Quick Ratio | 0.23 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.31 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -142.94% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 374.58% |
| Weighted Average Cost of Capital (WACC) | 21.48% |
| Revenue Per Employee | $36,687 |
| Profits Per Employee | -$375,820 |
| Employee Count | 67 |
| Asset Turnover | 0.29 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -96.43% in the last 52 weeks. The beta is 1.14, so VolitionRx's price volatility has been higher than the market average.
| Beta (5Y) | 1.14 |
| 52-Week Price Change | -96.43% |
| 50-Day Moving Average | 1.08 |
| 200-Day Moving Average | 3.70 |
| Relative Strength Index (RSI) | 20.52 |
| Average Volume (20 Days) | 1,007,871 |
Short Selling Information
The latest short interest is 538,529, so 6.46% of the outstanding shares have been sold short.
| Short Interest | 538,529 |
| Short Previous Month | 322,418 |
| Short % of Shares Out | 6.46% |
| Short % of Float | 8.09% |
| Short Ratio (days to cover) | 2.07 |
Income Statement
In the last 12 months, VolitionRx had revenue of $2.46 million and -$25.18 million in losses. Loss per share was -$3.80.
| Revenue | 2.46M |
| Gross Profit | 2.46M |
| Operating Income | -19.45M |
| Pretax Income | -25.73M |
| Net Income | -25.18M |
| EBITDA | -18.57M |
| EBIT | -19.45M |
| Loss Per Share | -$3.80 |
Balance Sheet
The company has $2.79 million in cash and $11.41 million in debt, with a net cash position of -$8.62 million or -$1.03 per share.
| Cash & Cash Equivalents | 2.79M |
| Total Debt | 11.41M |
| Net Cash | -8.62M |
| Net Cash Per Share | -$1.03 |
| Equity (Book Value) | -33.54M |
| Book Value Per Share | -2.67 |
| Working Capital | -9.40M |
Cash Flow
In the last 12 months, operating cash flow was -$19.56 million and capital expenditures -$21,969, giving a free cash flow of -$19.58 million.
| Operating Cash Flow | -19.56M |
| Capital Expenditures | -21,969 |
| Depreciation & Amortization | 874,461 |
| Net Borrowing | 1.10M |
| Free Cash Flow | -19.58M |
| FCF Per Share | -$2.35 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -791.16% |
| Pretax Margin | -1,046.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VolitionRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -44.16% |
| Shareholder Yield | -44.16% |
| Earnings Yield | -619.28% |
| FCF Yield | -481.66% |
Analyst Forecast
The average price target for VolitionRx is $16.57, which is 3,294.80% higher than the current price. The consensus rating is "Buy".
| Price Target | $16.57 |
| Price Target Difference | 3,294.80% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 132.80% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 28, 2026. It was a reverse split with a ratio of 1:20.
| Last Split Date | Apr 28, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |